Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445465 | 0.82 | GLA (0.61) | GLANPSR1TRPA1ABCB1MAOB | |
| SCHEMBL16645282 | 0.78 | GLA (0.52) | GLANPSR1MDM2 | |
| SCHEMBL3088858 | 0.78 | GLA (0.52) | GLANPSR1TRPA1MAOBDAO | |
| SCHEMBL15648921 | 0.78 | GLA (0.52) | GLANPSR1MAOBDAOMDM2 | |
| SCHEMBL7417047 | 0.77 | GLA (0.66) | GLANPSR1MDM2 | |
| SCHEMBL2673218 | 0.75 | GLA (0.42) | GLATRPA1IDH1MAOBDAO | |
| SCHEMBL16632922 | 0.75 | GLA (0.49) | GLANPSR1DAOHTR2B | |
| SCHEMBL3093178 | 0.74 | GLA (0.58) | GLANPSR1ABCB1GRM5FFAR1 | |
| SCHEMBL1499445 | 0.73 | GLA (0.45) | GLATRPA1IDH1MAOBFFAR1 | |
| SCHEMBL8958986 | 0.73 | GLA (0.57) | GLANPSR1MAOBDAOMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| EP-3057951-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| WO-2015057205-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-6759384-B1 | LOW MOLECULAR WEIGHT ANTICOAGULANTS WITHOUT SIDE EFFECTS; DERIVATIVES OF AT LEAST PROLINE, LEUCINE AND ARGININE SEQUENCE | AVENTIS PHARMACEUTICALS INC. | 2004-07-06 | — | — | US | disclosed |
| EP-0758341-B1 | FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1384725-A2 | Factor Xa inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-5849510-A | Factor Xa inhibitors | SELECTIDE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | GLA 2334/4885NPSR1 258/4885TRPA1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.